XTL Biopharmaceuticals Ltd. (XTLB) Stock Ticker
XTLB right now
Market factors today
Unlock the full XTLB picture
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
XTLB stock facts
| Ticker symbol | XTLB |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.1M |
| CEO | Noam Band |
| Employees | 10 |
| Headquarters | Herzliya, TA, IL |
| IPO date | 2005-09-01 |
| Website | www.xtlbio.com |
What you can see for XTLB on Tickr
Live XTLB price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the XTLB report.
Rankings
FAQ
What is the ticker symbol for XTL Biopharmaceuticals Ltd.?
The ticker symbol for XTL Biopharmaceuticals Ltd. is XTLB, listed on the NASDAQ Capital Market.
What is XTLB?
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company…